SEATTLE — The effects of aflibercept treatment in the three arms of the PULSAR study were not affected by baseline characteristics, according to four subgroup analyses presented at the American Society of Retina Specialists annual meeting.
In PULSAR, patients with treatment-naive wet age-related macular degeneration were randomly assigned to three arms, receiving aflibercept 8 mg every 12 weeks, aflibercept 8 mg every 16 weeks or aflibercept 2 mg every 8 weeks, all after three initial monthly injections. The primary endpoint was visual acuity at week 48.
In the first subgroup analysis,